Abstract Purpose of Review Prostate cancer (PCa) is amongst the most common cancers in
men worldwide. Cardiovascular (CV) risk factors and CV disease (CVD) are common …

The integral role of the hypothalamic–pituitary–gonadal axis in reproductive processes
makes it a prime therapeutic target. By inhibiting sex steroid synthesis, gonadotropin …

Background Comorbidities among cancer survivors remain a serious healthcare burden and
require appropriate management. Using two widely used frailty indicators, this study aimed …

Purpose Androgen deprivation therapy (ADT) is the mainstay for the management of
metastatic prostate cancer. Available pharmaceutical ADTs include gonadotropin-releasing …

Background We aimed to determine whether cardiovascular (CV) risk in patients with
prostate cancer (PCa) differs between those who receive gonadotropin‐releasing hormone …

The last decade has witnessed a paradigm shift in cancer therapy, from non-specific
cytotoxic chemotherapies to agents targeting specific molecular mechanisms. Nonetheless …

Background The impact of gonadotropin-releasing hormone (GnRH) antagonist and agonist
(GnRHa) treatment on cardiovascular disease (CVD) risk in prostate cancer (PCa) remains …

In this study using national health insurance data, we investigated the risk of ischemic heart
disease (IHD) and stroke among prostate cancer (PC) survivors compared with the general …

Introduction Androgen deprivation therapy (ADT) is a key treatment modality in the
management of prostate cancer (PCa), especially for patients with metastatic disease …

Background. Cardiovascular disease (CVD) is a common comorbidity in patients with
prostate cancer. In this review, we summarize the published literature on the association of …